The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Hepatocellular carcinoma (HCC) arises from hepatocytes through the sequential
accumulation of multiple genomic and epigenomic alterations resulting from Darwinian …

Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell
signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues …

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …

There has been a resurgence of interest in the use of phenotypic screens in drug discovery
as an alternative to target-focused approaches. Given that oncology is currently the most …

Treatment options for patients with hepatocellular carcinoma are rapidly changing based on
positive results from phase 3 trials of targeted and immune-based therapies. More agents …

Genome-wide identification of the mechanism of action (MoA) of small-molecule compounds
characterizing their targets, effectors, and activity modulators represents a highly relevant yet …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

Purpose Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased
anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our …

Data from many preclinical studies, including those using cellular models of colorectal,
gastric, gastro-oesophageal and gastro-oesophageal junction cancers, indicate that the …